Cinnamon / Casp3 Cancer Research Results

Cin, Cinnamon: Click to Expand ⟱
Features:
Cinnamon is a spice from inner bark from several tree species.
Cinnamon refers primarily to bark extracts from Cinnamomum verum (Ceylon cinnamon) and Cinnamomum cassia. Bioactive constituents include cinnamaldehyde, cinnamic acid derivatives, procyanidins, and polyphenols. In cancer models, cinnamon extracts and cinnamaldehyde are most frequently reported to exert anti-proliferative, pro-apoptotic, anti-inflammatory, and anti-angiogenic effects. Mechanistic themes include suppression of NF-κB and PI3K/AKT signaling, modulation of MAPK pathways, induction of mitochondrial apoptosis, and context-dependent ROS elevation in tumor cells. Some studies report inhibition of HIF-1α and glycolytic signaling, though cinnamon is not a direct enzymatic Warburg inhibitor. Effects vary substantially depending on species (Ceylon vs Cassia), preparation (aqueous vs ethanol extract), and dose. Human oncology data remain limited and largely preclinical.

-Cinnamaldehyde (CA), an active compound derived from the natural plant cinnamon. CA is an aromatic aldehyde compound, constituting approximately 65% of cinnamon extract
- See also HCA, a derivative of CA

Biological activity, cinnamaldehyde from Ceylon cinnamon:
Antimicrobial activity: 10-50 μM
Antioxidant activity: 10-100 μM
Anti-inflammatory activity: 20-50 μM
Anticancer activity: 50-100 μM
Cardiovascular health: 20-50 μM

5 g of Ceylon cinnamon might contain roughly between 30 mg and 150 mg of cinnamaldehyde, with an approximate mid-range estimate of about 70 mg.
Assuming a moderate supplemental intake 50–200 mg of cinnamaldehyde, peak plasma levels might be anticipated in the vicinity of 1–10 μM.

Primary mechanisms (ranked):

  1. Suppression of inflammatory and survival signaling, especially NF-κB, AP-1, COX-2, PI3K/AKT, and related anti-apoptotic programs.
  2. Induction of mitochondrial apoptosis and cell-cycle arrest in cancer models.
  3. Anti-metastatic and anti-invasive effects linked to glycolysis/HK2 suppression, migration inhibition, and EMT-related signaling changes.
  4. Anti-angiogenic activity through VEGF/VEGFR2/HIF-1α and downstream MAPK signaling modulation.
  5. Redox modulation, with antioxidant/NRF2 activation in normal-cell stress contexts but ROS elevation and apoptosis in some tumor models.

Bioavailability / PK relevance: Cinnamon is compositionally variable; cinnamaldehyde is lipophilic, rapidly absorbed and metabolized, and systemic exposure after oral intake is likely much lower than many in-vitro anticancer concentrations. Extract formulation, species, dose, food matrix, and first-pass metabolism materially affect exposure.

In-vitro vs systemic exposure relevance: Many anticancer studies use extract concentrations or cinnamaldehyde levels that may exceed achievable free systemic exposure after ordinary oral intake. Local gastrointestinal exposure may be more plausible than systemic tumor exposure.

Clinical evidence status: Preclinical for oncology. Cinnamon has human RCT/meta-analysis literature mainly in metabolic/inflammatory endpoints, but no established clinical anticancer indication. Translational constraints include variable extract chemistry, cassia coumarin hepatotoxicity risk, CYP/herb-drug interaction potential, and uncertain tumor-achievable exposure.

Cinnamon Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NF-κB AP-1 inflammatory survival signaling NF-κB ↓; AP-1 ↓; COX-2 ↓; Bcl-2 family survival tone ↓ Inflammatory tone ↓ R, G Anti-inflammatory and anti-survival signaling Core mechanism for cinnamon extract and cinnamaldehyde; model-dependent but repeatedly reported.
2 PI3K AKT mTOR growth signaling PI3K/AKT ↓; proliferation ↓; apoptosis ↑ ↔ or stress protection ↑ R, G Growth-signal suppression Most relevant for cinnamaldehyde-rich preparations; linked to colorectal and other cancer models.
3 Mitochondrial apoptosis Bax ↑; Bcl-2 ↓; mitochondrial dysfunction ↑; caspase activation ↑ ↔ at lower exposure; cytotoxicity risk at high exposure G Apoptotic induction Central anticancer mechanism but often requires concentrations above dietary exposure.
4 Glycolysis and HK2 driven invasion HK2 ↓; G6P/F6P production ↓; migration ↓; invasion ↓ ↔ G Anti-metastatic metabolic suppression Mechanistically important for metastatic dissemination models; not a broad direct Warburg enzyme inhibitor claim.
5 VEGF VEGFR2 HIF-1α angiogenesis axis VEGF ↓; HIF-1α ↓; tumor angiogenesis ↓ Angiogenesis ↑ in repair contexts; VEGF-stimulated pathological signaling may be ↓ R, G Context-dependent angiogenesis normalization Direction differs by context: anti-angiogenic in tumor models, but potentially pro-repair in normal tissue wound-healing/endothelial recovery settings.
6 ROS redox stress ROS ↑ and apoptosis ↑ in some tumor models (dose-dependent) ROS ↓ or antioxidant response ↑ at lower exposure P, R Context-dependent redox modulation Not simply antioxidant or pro-oxidant; direction depends on compound, dose, exposure time, and cell stress state.
7 NRF2 antioxidant response NRF2 ↑ may be protective or resistance-relevant (context-dependent) NRF2 ↑; cytoprotective gene expression ↑ R, G Stress-response activation Important safety/normal-cell protection axis; in cancer it may be double-edged if persistent NRF2 supports survival.
8 Cell-cycle regulation G1 or G2/M arrest ↑; cyclin/CDK signaling ↓ ↔ G Cytostasis Secondary to upstream growth and stress signaling changes.
9 MAPK stress signaling JNK/p38 modulation ↑; ERK modulation mixed ↔ or inflammatory MAPK ↓ P, R Signal reprogramming Direction varies by model and stimulus; best treated as contextual rather than primary.
10 Clinical Translation Constraint Systemic exposure uncertain; in-vitro dose gap likely Cassia coumarin hepatotoxicity risk; CYP interaction potential G Translation limitation Ceylon cinnamon is preferred for repeated higher intake because cassia generally has higher coumarin content.

TSF: P = 0–30 min (redox and early signaling effects), R = 30 min–3 hr (acute pathway modulation), G = >3 hr (apoptosis, angiogenesis, phenotype changes).



Casp3, CPP32, Cysteinyl aspartate specific proteinase-3: Click to Expand ⟱
Source:
Type:
Also known as CP32.
Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death.
As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression.
Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy.
Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent.
On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer.
Procaspase-3 is a apoptotic marker protein.
Prognostic significance:
• High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers.
• Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers.
Scientific Papers found: Click to Expand⟱
6165- Cin,  doxoR,    Cinnamaldehyde potentiates cytotoxic and apoptogenic effects of doxorubicin in prostate cancer cell line
- in-vitro, Pca, PC3
ChemoSen↑, ROS↑, Casp3↑, Casp7↑,
6356- Eug,  Cin,    Investigating the Molecular Mechanisms of the Anticancer Effects of Eugenol and Cinnamaldehyde Against Colorectal Cancer (CRC) Cells In Vitro
- in-vitro, CRC, SW-620 - in-vitro, CRC, Caco-2 - in-vitro, Nor, NCM460
P21↑, ChemoSen↑, Casp3↑, IL4↓, IL8↓, ROS↑, NRF2↑, HO-1↑, EMT↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

HO-1↑, 1,   NRF2↑, 1,   ROS↑, 2,  

Cell Death ⓘ

Casp3↑, 2,   Casp7↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL4↓, 1,   IL8↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 2,  
Total Targets: 10

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Casp3, CPP32, Cysteinyl aspartate specific proteinase-3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:62  Target#:42  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page